IRESSA J Code: J8565

Drug & Product Overview

HCPCS Descriptor Gefitinib, oral, 250 mg

HCPCS Added Date January 1, 2005

Manufacturer Multiple Manufacturers

Route of Administration Oral

Generic Status Multi-Source; Generic

Dosage Form Tablet | Tablet, Coated | Tablet, Film Coated

About IRESSA

Iressa is a medication aligned to the HCPCS J Code: J8565 for billing, pricing, and reimbursement purposes in the United States. This Oncology medication is administered via the oral route and manufactured by multiple companies.

Manufacturers, reach out to us to add more information.

NDC Code Information

5 NDC packages are crosswalked to J8565. Package detail is available to logged-in subscribers.

NDC Code	Drug	Manufacturer	Billing Units / Pkg	Package Size
•••••-••••-•• Log in to view	IRESSA
	IRESSA
	IRESSA
	IRESSA

Login to view 5 NDC packages View pricing, complete NDC-to-HCPCS alignments, and package details.

Login →

IRESSA Pricing & Reimbursement

J8565 Private Payer Reimbursement

$155.58 / HCPCS unit as of Jan 2026

National median reimbursement across major commercial payers.

Create an account on PayerPrice for more information →

IRESSA CPT Administration Codes

CPT Code	Description
81235	EGFR (epidermal growth factor receptor) (eg, non-small cell lung cancer) gene analysis, common variants (eg, exon 19 LREA deletion, L858R, T790M, G719A, G719S, L861Q)

Not on the CMS JW / JZ list

CMS does not include Iressa (J8565) on its list of HCPCS pertaining to single-dose containers. Per CMS guidelines, the JZ/JW wastage modifiers may not apply when billing J8565. Wastage billing guide →

IRESSA Medically Unlikely Edits (MUE)

The most billing units of J8565 Medicare will pay for one patient in one day, as published by CMS. 1 unit = 250 mg.

Practitioner Office & Hospital Outpatient

0 units / day

Not payable in this setting

MAI 3 · Date of Service Edit: Clinical. Per-day limit based on clinical expectations; excess units are denied but may be appealed with documentation of medical necessity. See all MUE limits →

IRESSA Clinical Information

Indications and drug classification.

Treated Diseases & Conditions

This list of indications is not exhaustive and may be subject to errors. The information on BuyandBill.com is intended for informational purposes only and should not be used for medical advice.

Metastatic non-small cell lung cancer (NSCLC) metastatic non-small cell lung cancer (NSCLC) metastatic non-small cell lung cancer (NSCLC) with EGFR exon 19 deletions or exon 21 (L858R) substitution mutations

Drug Class

Kinase Inhibitor [EPC]Protein Kinase Inhibitors [MoA]

Frequently Asked Questions

Is there an available Iressa billing and coding guide?

Our team has not identified a manufacturer-published source of billing and coding information for IRESSA.

Are there any available Iressa patient assistance programs?

Our team has not identified a manufacturer-published source of patient assistance information for IRESSA.

Where can I find Iressa prescribing information?

IRESSA prescribing information can be found at the link below. Please reach out to us if you believe this information to be innacurate or out of date. Visit Here →

Where can I find Iressa side effect information?

Our team has not yet identified a source of side effects information for IRESSA. Please check back in a few weeks.

Does billing IRESSA require JZ/JW wastage modifiers?

CMS does not include IRESSA (J8565) on its list of HCPCS pertaining to single-dose containers. Per CMS guidelines, the JZ/JW wastage modifiers may not apply when billing J8565. For more information, visit the link below.

About BuyandBill.com:

The BuyandBill.com team is dedicated to delivering high-quality coding and billing information for office-administered drugs. We continuously research HCPCS-coded medications to expand our resources and ensure data accuracy. Manufacturers: click here to sponsor your medication, and we will ensure the most accurate and detailed information is displayed.